313927--2/24/2010--CHURCH_&_DWIGHT_CO_INC_/DE/

related topics
{customer, product, revenue}
{product, market, service}
{product, liability, claim}
{cost, regulation, environmental}
{property, intellectual, protect}
{operation, international, foreign}
{operation, natural, condition}
{acquisition, growth, future}
{debt, indebtedness, cash}
{system, service, information}
{product, candidate, development}
{condition, economic, financial}
{regulation, government, change}
{financial, litigation, operation}
Economic conditions could adversely affect our business. If our trade customers discontinue or reduce distribution of our products or increase private label products, our sales may decline, adversely affecting our financial performance. If the reputation of one or more of our leading brands erodes our financial results could suffer. We have recently developed and commenced sales of a number of new products and line extensions, but if they do not gain widespread customer acceptance or if they cause sales of our existing products to decline, our financial performance could decline. We may discontinue products or product lines which could result in returns, asset write-offs and shutdown costs. We also may engage in product recalls that would reduce our cash flow and earnings. We face intense competition in a mature industry and we may be required to increase expenditures and accept lower profit margins to preserve or maintain our market share. Unless the markets in which we compete grow substantially, a loss of market share will result in reduced sales levels and declining operating results. Loss of the Crest tradename on our SPINBRUSH products could cause sales of that brand to decline. Providing price concessions or trade terms that are acceptable to our trade customers, or the failure to do so, could adversely affect our sales and profitability. Reductions in inventory by our trade customers, including as a result of consolidations in the retail industry, could adversely affect orders for our products in periods during which the reduction results. A continued shift in the retail market from food and drug stores to club stores and mass merchandisers could cause our sales to decline. Loss of any of our principal customers could significantly decrease our sales and profitability. Our substantial indebtedness could adversely affect our financial condition and ability to operate our businesses and repay the indebtedness. We may make acquisitions that result in dilution to our current stockholders or increase our indebtedness, or both. In addition, acquisitions that are not properly integrated or are otherwise unsuccessful could strain or divert our resources. Our condom product line could suffer if the spermicide N-9 is proved or perceived to be harmful. Our manufacturing and other facilities may be subject to disruption from events beyond our control. Price increases in raw and packaging materials or energy costs could erode our profit margins, which could harm operating results, and efforts to hedge against raw material price increases may adversely affect our operating results due to price declines. We are subject to various government regulations in the countries in which we operate that could adversely affect our business. We are subject to risks related to our international operations that could adversely affect our results of operations. Environmental matters create potential liability risks. Product liability claims could adversely affect the Company s sales and operating results. Failure to effectively utilize or successfully assert intellectual property rights could materially adversely affect our competitiveness. A failure of a key information technology system could adversely affect our ability to conduct business. Resolutions of tax disputes may impact our earnings and cash flow.

Full 10-K form ▸

related documents
313927--2/24/2009--CHURCH_&_DWIGHT_CO_INC_/DE/
313927--2/27/2008--CHURCH_&_DWIGHT_CO_INC_/DE/
868368--12/12/2008--ROCHESTER_MEDICAL_CORPORATION
868368--12/11/2009--ROCHESTER_MEDICAL_CORPORATION
868368--12/10/2010--ROCHESTER_MEDICAL_CORPORATION
8146--4/9/2010--ASTRO_MED_INC_/NEW/
18937--2/26/2008--CERADYNE_INC
225263--3/14/2007--NEWPORT_CORP
225263--3/11/2008--NEWPORT_CORP
225263--3/16/2006--NEWPORT_CORP
1423221--12/18/2009--Quanex_Building_Products_CORP
868368--12/26/2006--ROCHESTER_MEDICAL_CORPORATION
22252--5/3/2010--COMARCO_INC
878725--3/8/2006--EMBREX_INC_/NC/
868368--12/4/2007--ROCHESTER_MEDICAL_CORPORATION
225263--3/17/2009--NEWPORT_CORP
910406--9/13/2006--HAIN_CELESTIAL_GROUP_INC
914025--5/29/2007--PLANTRONICS_INC_/CA/
1014507--6/1/2006--SCHICK_TECHNOLOGIES_INC
1423221--12/18/2008--Quanex_Building_Products_CORP
1423221--12/20/2010--Quanex_Building_Products_CORP
887227--6/13/2007--CHOLESTECH_CORPORATION
785786--11/18/2009--PLEXUS_CORP
891288--3/29/2007--QUESTCOR_PHARMACEUTICALS_INC
70793--11/27/2007--NBTY_INC
70793--12/11/2006--NBTY_INC
1069183--2/29/2008--TASER_INTERNATIONAL_INC
851205--2/17/2009--COGNEX_CORP
1311538--6/29/2009--Castle_Brands_Inc
1324759--3/31/2010--Cereplast_Inc